Advertisement
Advertisement
KALA
KALA BIO, Inc. Common Stock
0.78
USDSponsored
+0.02
+2.78%
Aug 11, 13:31 UTC -4
Open
KALA Earnings Reports
Positive Surprise Ratio
KALA beat 16 of 35 last estimates.
46%
Next Report
Date of Next Report
Nov 17, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.33
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/-99.23%
KALA BIO, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, KALA reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.29 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.11% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.33 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
TELA Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.20
Surprise
-10.01%
Imunon, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.94
Actual
-$0.54
Surprise
+42.83%
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
Legend Biotech Corporation - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.07
Actual
$0.09
Surprise
+17.80%
Bicara Therapeutics Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.84
Actual
-$0.82
Surprise
+3.18%
Septerna, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.28
Surprise
+33.26%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Autolus Therapeutics plc - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.22
Actual
-$0.15
Surprise
+31.82%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.01
Actual
$0.05
Surprise
+400.00%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
FAQ
What were KALA BIO, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, KALA BIO, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to KALA BIO, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 5.11%, changed from $0.70 before the earnings release to $0.74 the day after.
When is KALA BIO, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 17, 2026.
What are the forecasts for KALA BIO, Inc. Common Stock's next earnings report?
Based on 4
analysts, KALA BIO, Inc. Common Stock is expected to report EPS of -$0.33 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement